• News
  • SAN DIEGO
  • BioTech

Sanofi, Isis win FDA advisers' support for cholesterol treatment

Sanofi and San Diego-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) won the support of U.S. regulatory advisers for its drug that treats a hyper form of high cholesterol in people with a rare genetic disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
65.09
  5.54  
+ 9.30%
10,081,817,000
67.12
22.25

Insider Trade Data

Date Insider Shares Type Value
12/01/2014 O Neil, Patrick R 1,500 Sell $76,815
12/01/2014 O Neil, Patrick R 1,500 Exchange $10,875
12/01/2014 O Neil, Patrick R 1,500 Sell $76,815
12/01/2014 O Neil, Patrick R 1,500 Exchange $10,875
11/03/2014 O Neil, Patrick R 1,500 Sell $69,255

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!